Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Prophylaxis With Caspofungin in High-Risk Liver Transplantation

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2006 by Grupo de Estudio de Infecciones en Transplantados.
Recruitment status was:  Recruiting
Sponsor:
Collaborator:
Merck Sharp & Dohme Corp.
Information provided by:
Grupo de Estudio de Infecciones en Transplantados
ClinicalTrials.gov Identifier:
NCT00333645
First received: June 4, 2006
Last updated: April 12, 2007
Last verified: December 2006
  Purpose
This is a non-comparative, open, multisite prospective estimation study to evaluate the efficacy and safety of caspofungin in the prophylactic treatment of adults who have received an orthotopic liver transplant and are at high risk of developing an invasive fungal infection. It is expected that the proportion of high-risk liver transplant recipients who develop a documented (proven or probable per European Organization for Research and Treatment of Cancer/Mycoses Study Group [EORTC/MSG] modified criteria) invasive fungal infection during the first 100 days after the onset of prophylaxis with caspofungin will be lower than 15%. It is also expected that the incidence of serious drug-related adverse events will be less than 25%.

Condition Intervention Phase
Liver Transplantation
Fungal Infection
Drug: Caspofungin
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Prophylaxis With Caspofungin for the Prevention of Invasive Fungal Infections in High-Risk Liver Transplant Recipients

Resource links provided by NLM:


Further study details as provided by Grupo de Estudio de Infecciones en Transplantados:

Primary Outcome Measures:
  • Absence of breakthrough proven/probable invasive fungal infection by day +100

Secondary Outcome Measures:
  • Absence of breakthrough proven/probable invasive aspergillosis by day +100
  • Discontinuation of study therapy due to a drug-related adverse event
  • Incidence of drug-related serious adverse event(s)
  • Incidence of drug-related adverse event(s)

Estimated Enrollment: 70
Study Start Date: October 2003
Estimated Study Completion Date: March 2007
  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age or older
  • Patient has received an orthotopic liver transplantation
  • Patient meets criteria, as defined per protocol, for being considered at high risk of developing an invasive fungal infection post-liver transplantation
  • For women of childbearing potential, patient must have a negative serum or urine pregnancy test

Exclusion Criteria:

  • Any systemic antifungal therapy (other than fluconazole for a maximum of 7 days) within 14 days of the administration of the study drug.
  • Documented (proven/probable) or suspected (possible) invasive fungal infection at the time of enrollment.
  • Abnormal laboratory values as defined per protocol.
  • Allergy, hypersensitivity, or any serious reaction to an echinocandin antifungal.
  • Patient not expected to survive at least 5 days.
  • Patient is pregnant or breast feeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00333645

Locations
Spain
Hospital de Cruces
Barakaldo, Spain, E-48903
Hospital Universitari Vall d'Hebron
Barcelona, Spain, E-08035
Hospital Universitario Virgen de las Nieves
Granada, Spain, E-18014
Complejo Hospitalario Juan Canalejo
La Coruña, Spain, E-15006
Hospital General Universitario Gregorio Marañón
Madrid, Spain, E-28007
Hospital Ramon y Cajal
Madrid, Spain, E-28034
Hospital Universitario Puerta de Hierro
Madrid, Spain, E-28035
Hospital 12 de Octubre
Madrid, Spain, E-28041
Complejo Hospitalario Carlos Haya
Malaga, Spain, E-29010
Complejo Hospitalario Universitario de Santiago
Santiago de Compostela, Spain, E-15706
Hospital Universitario Virgen del Rocío
Sevilla, Spain, E-41013
Hospital Universitario La Fe
Valencia, Spain, E-46009
Sponsors and Collaborators
Grupo de Estudio de Infecciones en Transplantados
Merck Sharp & Dohme Corp.
Investigators
Study Director: Jesus Fortun, MD Hospital Ramon y Cajal, Madrid, Spain
  More Information

Publications:
Fortun J, Muñoz P, Cisneros JM, et al. Antifungal prophylaxis with caspofungin in high-risk liver transplant recipients: a noncomparative, open-label prospective clinical trial. Clinical Microbiology & Infection 12 (suppl. 4): P684, 2006. [Abstract on an interim analysis performed on the first 15 patients enrolled in the study, presented as a poster at 2006 ECCMID meeting].

ClinicalTrials.gov Identifier: NCT00333645     History of Changes
Other Study ID Numbers: GESITRA-01  03-0409 (Spanish Drug Agency) 
Study First Received: June 4, 2006
Last Updated: April 12, 2007
Health Authority: Spain: Spanish Agency of Medicines

Keywords provided by Grupo de Estudio de Infecciones en Transplantados:
Liver transplantation
Invasive fungal infection
Invasive aspergillosis
Prophylaxis
Caspofungin

Additional relevant MeSH terms:
Infection
Mycoses
Caspofungin
Echinocandins
Antifungal Agents
Anti-Infective Agents

ClinicalTrials.gov processed this record on December 09, 2016